Is Boston Scientific Corp. overvalued or undervalued?

As of 1 October 2024, the valuation grade for Boston Scientific Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a P/E ratio of 86, an EV to EBITDA of 44.86, and a PEG ratio of 6.37, all of which are considerably higher than industry standards.
In comparison with peers, Boston Scientific's P/E ratio of 86 is notably higher than McKesson Corp.'s 57.12 and Cencora, Inc.'s 45.11, while its EV to EBITDA also exceeds McKesson's 37.52. Despite a strong return of 31.72% over the past year compared to the S&P 500's 10.26%, the elevated valuation metrics suggest that the stock may not be a sound investment at its current price of 102.36.